Dkn-01 Treated Patients with Recurrent Epithelial Endometrial (EEC) or Ovarian (EOC) Cancers Which Harbor Wnt Activating Mutations Have Longer Progression-Free Survival and Improved Clinical Benefit

Objective: Dickkopf-1 (DKK1) is a secreted modulator of Wnt signaling that promotes tumor cell proliferation, angiogenesis, and metastasis and contributes to an immune suppressive tumor microenvironment. Activating mutations of the Wnt/Beta-catenin dependent signaling pathway result in increased tumor production of DKK1. We assessed whether patients whose tumors harbor Wnt-activating mutations have improved clinical outcomes to DKN-01 (DKK1 antibody).